Please login to the form below
Merz acquire BioForm Medical
Merz Pharma have agreed to acquire BioForm Medical for $253m, expanding its presence in cosmetic pharmaceuticals
Merz Pharma Group have agreed to acquire BioForm Medical Inc (BFRM) for $253m, expanding its cosmetic pharmaceuticals portfolio. The privately held German pharmaceutical company already has a presence in anti-ageing skincare with their product Belotero - the world's first monophasic hyaluronic acid dermal filler with patented CPM technology.
Merz will pay $5.45 per BioForm share, a 60 per cent premium to the company's Thursday closing price.
BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins. The company is non profitable, though sales have been improving and last November BioForm narrowed its loss forecast for its fiscal year ending June 30.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout
- Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
- UK Vaccine Taskforce chief says first COVID-19 vaccines ‘likely to be imperfect’
- Send Us a Message
- Pharma, Technology, and Healthcare in the New Normal
- Solving the Caregiver Crisis Through Technology
- Therapeutic VR for Managing Pain & Improving Patient Outcomes
- Fishawack Health launches global ‘PsoriasIS NOT CONTAGIOUS’ mask campaign for World Psoriasis Day 2020
- The impact of COVID-19 on cancer care
- UK Vaccine Taskforce chief says first COVID-19 vaccines ‘likely to be imperfect’
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- The science of the deal
- Business development is more like child-raising than you might think...
- The other side of … rheumatoid arthritis
- For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
- How to lessen site burden with a targeted patient recruitment strategy
- Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
Quick links
Infographics
